Inclisiran: Prospective observational study. There is no treatment allocation. Patients who are eligible to receive inclisiran will be enrolled into this study.
This observational prospective study aims to evaluate the LDL-C change and adherence to inclisiran in combination with other lipid lowering therapies or lipid lowering treatments (LLTs) under conditions of routine clinical practice.
| Facility | City | Region | Status |
|---|---|---|---|
| Novartis Investigative Site | Feldkirch | Austria | |
| Novartis Investigative Site | Graz | Austria | |
| Novartis Investigative Site | Linz | Austria | |
| Novartis Investigative Site | Sankt Veit im Pongau | Austria | |
| Novartis Investigative Site | Vienna | Austria | |
| Novartis Investigative Site | Vienna | Austria | |
| Novartis Investigative Site | Shenzhen | Guangdong | |
| Novartis Investigative Site | Holon | Gush Dan | |
| Novartis Investigative Site | Petah Tikva | Israel | |
| Novartis Investigative Site | Tel Aviv | Israel | |
| Novartis Investigative Site | Kuala Lumpur | Kuala Lumpur | |
| Novartis Investigative Site | Kuala Lumpur | Malaysia | |
| Novartis Investigative Site | Riyadh | Saudi | |
| Novartis Investigative Site | Jeddah | Saudi Arabia | |
| Novartis Investigative Site | Tabuk | Saudi Arabia | |
| Novartis Investigative Site | Fribourg | CH | |
| Novartis Investigative Site | Basel | Switzerland | |
| Novartis Investigative Site | Geneva | Switzerland | |
| Novartis Investigative Site | Lausanne | Switzerland | |
| Novartis Investigative Site | Olten | Switzerland | |
| Novartis Investigative Site | Sankt Gallen | Switzerland | |
| Novartis Investigative Site | Zurich | Switzerland | |
| Novartis Investigative Site | Zurich | Switzerland | |
| Novartis Investigative Site | Abu Dhabi | Abu Dhabi Emirate | |
| Novartis Investigative Site | Dubai | United Arab Emirates | |
| Novartis Investigative Site | Abu Dhabi | United Arab Emirates | |
| Novartis Investigative Site | Al Ain City | United Arab Emirates | |
| Novartis Investigative Site | Dubai | United Arab Emirates | |
| Novartis Investigative Site | High Wycombe | Buckinghamshire | |
| Novartis Investigative Site | Louth | Lincolnshire | |
| Novartis Investigative Site | Sunderland | Tyne and Wear | |
| Novartis Investigative Site | Belfast | United Kingdom | |
| Novartis Investigative Site | Bromwich | United Kingdom | |
| Novartis Investigative Site | Burton-on-Trent | United Kingdom | |
| Novartis Investigative Site | Cardiff | United Kingdom | |
| Novartis Investigative Site | Hull | United Kingdom | |
| Novartis Investigative Site | Lancaster | United Kingdom | |
| Novartis Investigative Site | Liverpool | United Kingdom | |
| Novartis Investigative Site | London | United Kingdom | |
| Novartis Investigative Site | Middlesex | United Kingdom |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05399992 on ClinicalTrials.gov ↗ ← All trials in the UK